Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security

Table 5 Base case results of the health-economic model to determine the ICER of CSII therapy compared to MDI therapy, from the IMSS perspective

Outcomes
Efficacy	CSII	MDI	Absolute difference
Life expectancy (discounted years)	12.593	11.897	0.696
Life expectancy (undiscounted years)	25.036	22.508	2.528
QALYs	7.052	6.438	0.614

Costs	MXN (CSII)	USD (CSII)	MXN (MDI)	USD (MDI)	MXN (Δ)	USD (Δ)
Total costs	1,404,173	76,355	1,110,573	60,390	293,600	15,965
Treatment	693,515	37,712	281,555	15,310	411,960	22,401
Management	14,807	805	14,102	767	705	38
Cardiovascular disease	45,771	2,489	48,047	2,613	2,276	124
Renal care	204,628	11,127	215,608	11,724	10,980	597
Ulcer/amputation/neuropathy	296,320	16,113	323,908	17,613	27,588	1500
Eye care	137,213	7461	135,399	7363	1814	99
Hypoglycemia	10,003	544	90,044	4896	80,041	4352

Incremental cost effectiveness ratio^a					MXN	USD
Incremental cost effectiveness ratio per LYG					434,577	23,631
Incremental cost effectiveness ratio per QALY gained					478,020	25,993

^aResults are estimated using all decimal points included in the model, and as such show differences to results calculated using the data presented in the table

ISSN: 1478-7547